Composition of a VEGF antagonist and an anti-proliferative agent
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJocelyn Holash, Robert Jaffe, Limin Hu, George Yancopoulos
Life of this patent
Estimating the term…
Abstract
Methods of treating cancer and/or reducing or inhibiting tumor growth in a subject in need thereof, comprising administering pharmaceutical composition comprising a vascular endothelial cell growth factor (VEGF) antagonist, such as a VEGF trap, an anti-proliferative agent, such as taxol, and a pharmaceutically acceptable carrier.
Claims29
A method of treating cancer in a subject in need thereof, comprising administering to the subject a VEGF antagonist and an anti-proliferative agent such that the cancer is treated.
A method of treating cancer in a subject in need thereof, comprising administering to the subject a vascular endothelial growth factor (VEGF) antagonist and an anti-proliferative agent such that the cancer is treated, wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a) or Flt1D2.Flk1D3.FcΔC1(a), and the anti-proliferative agent is a paclitaxel, docetaxel, or a derivative, analogue, or mixture thereof.
A method of reducing tumor growth in a subject in need thereof, comprising administering to the subject a VEGF antagonist and an anti-proliferative agent, wherein the growth of the tumor is reduced.
A method of inhibiting tumor growth in a subject in need thereof, comprising administering to the subject a vascular endothelial cell growth factor (VEGF) antagonist in combination with an anti-proliferative agent, wherein tumor growth is inhibited.
A method of inhibiting or reducing tumor growth in a subject in need thereof, comprising administering to the subject a vascular endothelial cell growth factor (VEGF) antagonist in combination with an anti-proliferative agent, wherein tumor growth is inhibited, wherein the VEGF antagonist is a VEGF trap, and the anti-proliferative agent is selected from the group consisting of paclitaxel, docetaxel or a derivative, analogue, or mixture of paclitaxel and a platinum-based chemotherapeutic.
A pharmaceutical composition comprising a vascular endothelial cell growth factor (VEGF) antagonist, an anti-proliferative agent, and a pharmaceutically acceptable carrier.
A method of reducing the amount of a chemotherapeutic agent necessary to achieve a desired therapeutic effect, comprising administering the chemotherapeutic agent with a VEGF antagonist.
An article of manufacturing, comprising:
- (a) packaging material;
- and
- (b) a pharmaceutical agent contained within the packaging material, wherein the pharmaceutical agent comprises at least one dose of vascular endothelial growth factor (VEGF) trap and at least one anti-proliferative agent, and wherein the packaging material indicates that the VEGF antagonist and anti-proliferative agent can be used for treating cancer or reducing tumor growth.
Dependencies are inferred from the claim text.